Adaptimmune is presenting at ASCO, potentially providing updates on their drug development projects. Read more about ADAP ...

Shares of Adaptimmune Therapeutics were down 10% Friday after biotech powerhouse Genentech terminated a cell therapy ...

The termination of the Adaptimmune deal comes the same week Genentech said it will cut about 3% of its 436-person workforce.

By Ben Glickman Roche Group-member Genentech said Thursday it had received regulatory approval for its treatment for patients with an early-stage form ...

Graig Suvannavejh has given his Buy rating due to a combination of factors that suggest Adaptimmune Therapeutics (ADAP) has a solid outlook despite the recent end of its collaboration with Genentech.

“At Genentech, our goal is to give patients the best chance of cure by bringing effective, targeted treatments to early-stage disease before their cancer has spread. This approval brings us one step ...

For the acquisition, Century will pay an upfront cost of $35m in cash and shares, along with a $10m one-time milestone ...

Although Genentech isn’t closing any facilities, its layoffs are by far the biggest. The South San Francisco-based ...

Regeneron Pharmaceuticals shares have dipped 3% since the U.S. Department of Justice filed a complaint accusing the company ...

Biotech giants Genentech and Sanofi are laying off hundreds of workers at their facilities in South San Francisco. The San Francisco Business Times reported Genentech's parent company Roche would ...

And the threat of shortages has a chance to be exacerbated further, at least in the short term, due to pending bipartisan ...

Genentech, Hoffmann-La Roche, and Biogen have settled their BPCIA litigation against Dr. Reddy’s Laboratories (“DRL”) and Fresenius Kabi. As we previously reported, Genentech, Hoffmann-La ...